Skip to Main Content

Someone please give Pascal Soriot a dictionary.

During an earnings conference call, the AstraZeneca chief executive disclosed the company would not raise prices in the U.S. for the rest of year. Other drug makers have taken the same step in response to pressure from the Trump administration, but he insisted this was “our plan … all along.”


Given the timing, this is questionable. But then Soriot made an even more curious remark.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.